Compass Therapeutics (CMPX) Cash from Operations (2018 - 2026)
Compass Therapeutics (CMPX) reported Cash from Operations of 17269000.0 for Q1 2026, down 30.75% on a YoY basis from 24935930.03 in Q1 2025, and down 30.29% sequentially from 13254000.0 in Q4 2025.
Compass Therapeutics (CMPX) Cash from Operations (2018 - 2026) Analysis & Trends
Compass Therapeutics (CMPX) has 9 years of Cash from Operations data on file, last reported at 17269000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations fell 30.75% year-over-year to 17269000.0; the trailing twelve-month figure through Mar 2026 stood at 53204000.0 (down 20.44% YoY), and the FY2025 full-year result was 49143000.0, down 9.56% from the prior year.
- Cash from Operations declined to 17269000.0 in Q1 2026, from 13254000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 4600000.0 in Q2 2022 to a low of 17269000.0 in Q1 2026.
- A 5-year average of 10941764.71 and a median of 10942000.0 in 2022 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations plunged 216.52% in 2022 and soared 45.88% in 2023, its largest moves.
- Tracing CMPX's Cash from Operations over 5 years: stood at 10641000.0 in 2022, then decreased by 16.1% to 12354000.0 in 2023, then grew by 25.84% to 9162000.0 in 2024, then tumbled by 44.66% to 13254000.0 in 2025, then plunged by 30.29% to 17269000.0 in 2026.
- Business Quant data shows CMPX's Cash from Operations at 17269000.0 in Q1 2026, 13254000.0 in Q4 2025, and 10849000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Compass Therapeutics | 395.17 Mn | 200.48 Mn | - | -17.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.27 Mn |
| Mar 31, 2026 | -17.27 Mn |
| Dec 31, 2025 | -13.25 Mn |
| Dec 31, 2025 | -13.25 Mn |
| Sep 30, 2025 | -10.85 Mn |
| Sep 30, 2025 | -10.85 Mn |
| Jun 30, 2025 | -11.83 Mn |
| Jun 30, 2025 | -11.83 Mn |
| Mar 31, 2025 | -13.21 Mn |
| Mar 31, 2025 | -13.21 Mn |
| Dec 31, 2024 | -9.16 Mn |
| Dec 31, 2024 | -9.16 Mn |
| Sep 30, 2024 | -11.05 Mn |
| Sep 30, 2024 | -11.05 Mn |
| Jun 30, 2024 | -10.75 Mn |
| Jun 30, 2024 | -10.75 Mn |
| Mar 31, 2024 | -13.89 Mn |
| Mar 31, 2024 | -13.89 Mn |
| Dec 31, 2023 | -12.35 Mn |
| Dec 31, 2023 | -12.35 Mn |